Get the latest tech news
First Axiom Space-Tested Research Drug Goes to Clinical Trials: Accelerating Cancer Research in Microgravity
Jun 02, 2025 - Pharmaceuticals Leveraging Microgravity to Accelerate Cancer Research
Microgravity is an environment where tumors have been shown to grow more quickly, and where better drug candidates may be selected for improved odds of working in patients, especially for those with faster disease progressions. “We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” said Tejpaul Bhatia, CEO of Axiom Space. With California Institute for Regenerative Medicine (CIRM), NASA, and angel investor support, Aspera is the first company to develop an FDA IND approved small molecule inhibitor of ADAR1 splicing for myelofibrosis and acute myeloid leukemia that may also have implications for preventing recurrence and immune evasion in 20 cancers.
Or read this on r/technology
